Dihexa is a small peptide that has been developed to potently improve certain cognitive function of potential trauma-based brain disorders and neurodegenerative conditions through increased synaptogenesis
While experiences vary, the most commonly discussed side effects include injection site irritation, headaches, nausea, fatigue, dizziness, and temporary digestive discomfort
Future billing changes will directly impact provider reimbursement strategies
This suggests that impaired B12 sensitivity is common in CHD, and high-dose B12 supplementation may provide limited benefits for reducing cardiovascular risk
Self-administration could lead to incorrect technique or adverse reactions
In South Australia, the Controlled Substances Act 1984 (SA) makes it an offence to prescribe, purchase, use, sell or supply peptides without sufficient authorisation